WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Google Secures Pentagon AI Deal for Classified Projects 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2016 -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a biopharmaceutical company developing novel treatments for nonalcoholic steatohepatitis (NASH), and other serious immuno-inflammatory and fibrotic diseases, will report financial results for the quarter ended December 31, 2015 after market close on Thursday March 3, 2016. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Date: March 3, 2016
Time: 1:30 PM PT
Listen via Internet: http://ir.tobiratherapeutics.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=71315&k=7CAD412C
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
Password: 47016109
A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 47016109.
About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at www.tobiratherapeutics.com.
CONTACT: Tobira Investor & Media Contact
Ian Clements, PhD
+1 (650) 351-5013
[email protected]
Canale Communications Media Contact
Pam Lord
+1 (619) 849-6003
[email protected]
